10x Genomics (NASDAQ: TXG) grants 8,829 RSUs to director Suliman

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

SULIMAN SHEHNAAZ reported acquisition or exercise transactions in this Form 4 filing.

10x Genomics director Shehnaaz Suliman received an equity award of 8,829 restricted stock units (RSUs) of Class A Common Stock. The grant has no cash purchase price and increases her direct holdings to 37,445 shares. The RSUs vest in four equal quarterly installments starting on May 21, 2026, as long as she continues as a service provider.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SULIMAN SHEHNAAZ

Role null

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	8,829	$0.00	--

Holdings After Transaction: Class A Common Stock — 37,445 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 8,829 RSUs Price per share: $0.00 per share Shares held after: 37,445 shares +2 more

5 metrics

RSUs granted 8,829 RSUs Award of restricted stock units to director on June 4, 2026

Price per share $0.00 per share Grant price for RSU award

Shares held after 37,445 shares Total Class A Common Stock directly held after transaction

Vesting start date May 21, 2026 First quarterly vesting date for RSUs

Vesting schedule 1/4 each quarterly anniversary Four equal installments from May 21, 2026, subject to continued service

Key Terms

restricted stock units ("RSUs"), contingent right, Class A Common Stock, service provider

4 terms

restricted stock units ("RSUs") financial

"Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of Class A Common Stock"

Class A Common Stock financial

"Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting."

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

service provider financial

"subject to the Reporting Person continuing as a service provider through each such date."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/08/2026 - 07:26 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SULIMAN SHEHNAAZ

(Last)

(First)

(Middle)

C/O 10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON

CALIFORNIA

94588

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	06/04/2026		A		8,829⁽¹⁾	A	$0	37,445	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Randy Wu, as Attorney-in-Fact for Shehnaaz Suliman	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did 10x Genomics (TXG) report for Shehnaaz Suliman?

10x Genomics reported that director Shehnaaz Suliman received an award of 8,829 restricted stock units of Class A Common Stock. These RSUs are a form of equity compensation, not an open-market share purchase, and vest over time based on continued service.

How many 10x Genomics (TXG) shares does Shehnaaz Suliman hold after this RSU grant?

After the grant of 8,829 restricted stock units, Shehnaaz Suliman directly holds 37,445 shares of 10x Genomics Class A Common Stock. This figure reflects her position following the reported transaction in the Form 4 insider filing.

What are the vesting terms of the new RSUs granted at 10x Genomics (TXG)?

The 8,829 restricted stock units vest in four equal quarterly installments. Vesting begins on May 21, 2026, with one-quarter vesting on each quarterly anniversary, provided Shehnaaz Suliman continues as a service provider through each applicable vesting date.

Did Shehnaaz Suliman pay cash for the 10x Genomics (TXG) RSU award?

No, the RSU award carries a price per share of $0.00 because restricted stock units are a compensation grant. They convert into shares of Class A Common Stock upon vesting, rather than being purchased in the open market for cash.

Is the 10x Genomics (TXG) Form 4 transaction a stock purchase or a compensation grant?

The Form 4 transaction is a compensation grant, not a stock purchase. Shehnaaz Suliman received 8,829 restricted stock units as a grant, which will settle into shares of Class A Common Stock as they vest over time.